Patient characteristics, clinical care, resource use, and outcomes associated with hospitalization for COVID-19 in the Toronto area

Amol A. Verma, Tejasvi Hora, Hae Young Jung, Michael Fralick, Sarah L. Malecki, Lauren Lapointe-Shaw, Adina Weinerman, Terence Tang, Janice L. Kwan, Jessica J. Liu, Shail Rawal, Timothy C.Y. Chan, Angela M. Cheung, Laura C. Rosella, Marzyeh Ghassemi, Margaret Herridge, Muhammad Mamdani, Fahad Razak
doi: https://doi.org/10.1101/2020.12.15.20248199

Abstract

Background Patient characteristics, clinical care, resource use, and outcomes associated with hospitalization for coronavirus disease (COVID-19) in Canada are not well described.

Methods We described all adult discharges from inpatient medical services and medical-surgical intensive care units (ICU) between November 1, 2019 and June 30, 2020 at 7 hospitals in Toronto and Mississauga, Ontario. We compared patients hospitalized with COVID-19, influenza and all other conditions using multivariable regression models controlling for patient age, sex, comorbidity, and residence in long-term-care.

Results There were 43,462 discharges in the study period, including 1,027 (3.0%) with COVID-19 and 783 (2.3%) with influenza. Patients with COVID-19 had similar age to patients with influenza and other conditions (median age 65 years vs. 68 years and 68 years, respectively, SD<0.1). Patients with COVID-19 were more likely to be male (59.1%) and 11.7% were long-term care residents. Patients younger than 50 years accounted for 21.2% of all admissions for COVID-19 and 24.0% of ICU admissions. Compared to influenza, patients with COVID-19 had significantly greater mortality (unadjusted 19.9% vs 6.1%, aRR: 3.47, 95%CI: 2.57, 4.67), ICU use (unadjusted 26.4% vs 18.0%, aRR 1.52, 95%CI: 1.27, 1.83) and hospital length-of-stay (unadjusted median 8.7 days vs 4.8 days, aRR: 1.40, 95%CI: 1.20, 1.64), and not significantly different 30-day readmission (unadjusted 8.6% vs 8.2%, aRR: 1.01, 95%CI: 0.72, 1.42).

Interpretation Adults hospitalized with COVID-19 during the first wave of the pandemic used substantial hospital resources and suffered high mortality. COVID-19 was associated with significantly greater mortality, ICU use, and hospital length-of-stay than influenza.

Introduction

The global coronavirus disease 2019 (COVID-19) pandemic has disrupted healthcare systems around the world. Studies in the United States, United Kingdom, and China report that patients hospitalized with COVID-19 have high rates of critical illness and mortality.1–5 Two small Canadian case series have described care for critically ill patients with COVID-19 and found that mortality was up to 25%.6,7 However, hospitalizations for COVID-19 in Canada are not well described, particularly outside of ICU. More than 80% of patients hospitalized for COVID-19 may not require intensive care.1,4 The features of COVID-19 hospitalizations in Canada may differ from other countries due to differences in populations, public health, and health care systems. Case fatality rates for COVID-19 vary dramatically worldwide.8 In Canada, COVID-19 has disproportionately affected urban and suburban ethnic minority populations,9 and residents of Long-Term Care facilities10,11.

Seasonal influenza is a useful comparator to assess the severity of illness associated with COVID-1912 as it is another respiratory virus with high attendant morbidity and mortality, and it is familiar to the general public. The relative severity of COVID-19 and seasonal influenza remains controversial.13 The preponderance of evidence suggests that COVID-19 has greater morbidity and mortality but the magnitude of this difference remains uncertain.13–18 The purpose of this study was to describe patient characteristics, resource use, clinical care, and outcomes for patients hospitalized with COVID-19 at 7 hospitals in Toronto and Mississauga, Ontario, Canada. We compared hospitalizations for COVID-19 with hospitalizations for influenza and all other medical ward and intensive care unit (ICU) admissions.

Methods

Design and Setting

This retrospective cohort study was conducted at 7 large hospitals (5 academic and 2 community-based teaching hospitals) in Toronto and Mississauga, Ontario, participating in GEMINI, a hospital research collaborative.19 Research ethics board approval was obtained from all participating organizations.

Data Collection

Administrative and clinical data were collected from hospital information systems for GEMINI as has previously been described in detail 19,20. Manual validation of a subset of GEMINI data found 98-100% accuracy compared to detailed medical record review.20 Patient demographics, hospital resource use, and outcomes were collected from hospitals as reported to the Canadian Institute for Health Information (CIHI) Discharge Abstract Database and National Ambulatory Care Reporting System. Additional clinical data, including laboratory test results, radiology tests, vital signs and in-hospital medication orders were extracted from hospital information systems. At one hospital, vital signs were manually abstracted only for patients with COVID-19 because they were not available through electronic extraction.

Study population

We included all adult patients (greater than 18 years) discharged from an inpatient medical service or medical-surgical intensive care unit (ICU), including coronary care units, between November 1, 2019 and June 30, 2020. Medical services included all medical specialties (e.g. general medicine, cardiology, respirology, etc.). This captures all hospitalizations for COVID-19 and influenza and their medical complications but misses a small number of patients hospitalized for non-medical reasons (e.g. surgical, psychiatric, obstetrical) who were incidentally found to have COVID-19 or influenza and were not subsequently transferred to a medical service.

Exposures

We categorized patients into three mutually-exclusive categories: COVID-19, influenza, and other medical admissions. We identified patients with COVID-19 based on International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10-CA) codes U07.1 (“COVID-19 diagnosis confirmed by a laboratory test”)21 and U07.2 (“COVID-19 diagnosed clinically or epidemiologically but lab results inconclusive, unavailable, or not performed”).21 We identified patients with influenza based on ICD-10-CA codes J09-J11, which an Ontario hospital study found to be 91% sensitive and 97% specific.22 Cases with both influenza and COVID-19 were categorized in the COVID-19 group. All admissions other than COVID-19 and influenza were considered for “other” conditions.

Outcomes and Process Measures

We report in-hospital mortality and readmission to any medical or medical-surgical ICU service at any participating hospital within 7- and 30-days of discharge. To report readmission, we excluded patients who died and those discharged within the last 7-days and 30-days of the study period, respectively. We also report total hospital length-of-stay, emergency department (ED) length-of-stay, admission to the ICU, and ICU length-of-stay. We also describe use of thoracic computed tomography (CT) and in-hospital use of respiratory-acting antibiotics23–25 (see Appendix for details), anticoagulants, and systemic corticosteroids, as captured by medication orders after admission. These medications were selected because their prescribing may be associated with COVID-19,26,27 although the study period was prior to the publication of the RECOVERY dexamethasone trial results.26 We describe the use of invasive mechanical ventilation, renal replacement therapy (including both newly initiated and chronic hemodialysis and peritoneal dialysis), gastrointestinal endoscopy, and bronchoscopy identified using Canadian Classification of Health Interventions codes.

Patient Characteristics

We report patient age, sex, residence in long-term care facility, and transfer from acute care hospital as reported by hospitals to CIHI. We categorized comorbid conditions based on ICD-10-CA codes using the Clinical Classification Software Refined (CCSR),28,29 the Charlson Comorbidity Index,30 and the Hospital Frailty Risk Score31,32. We report baseline laboratory test results and vital signs, defined as the first measurement that occurred between ED triage and 48 hours after admission.

Statistical Analysis

We compared baseline characteristics between groups using standardized differences (SD), with SD>0.1 suggesting imbalance between groups.33 We compared unadjusted differences in clinical care, resource use and clinical outcomes between groups using chi-square tests for categorical variables, one-way ANOVA for continuous variables with a normal distribution, and Kruskall-Wallis tests for continuous variables with a non-normal distribution. We used multivariable regression to compare outcomes between groups after adjusting for patient age, sex, Charlson score, residence in long-term care, and admitting hospital. Poisson regression34 was used for mortality, readmission, and ICU admission and negative binomial regression was used for hospital length-of-stay and ICU length-of stay. Separate models were fit to compare COVID-19 to influenza and COVID-19 to other conditions.

Subgroup and Sensitivity Analyses

First, we examined outcomes stratified by age groups. Second, we report patient characteristics and outcomes among the patients admitted to ICU. Third, we replicated all analyses after excluding COVID-19 diagnoses based on code U07.2 (patients with no laboratory confirmation). Finally, because participating hospitals are tertiary and quaternary care centres with large critical care units, we replicated analyses after including only patients admitted through the ED. This excluded interfacility transfers, which primarily involve patients transferred for critical care and might lead to an overestimation of illness severity.

Results

During the study period there were 43,462 discharges, representing 34,782 unique patients. There were 1,027 discharges (3.0%) with COVID-19 (944 laboratory-confirmed), representing 972 unique patients. These represented 23.5% of all Ontario hospitalizations for COVID-19 (N= 4,373)35 during the study period. There were 783 discharges (2.3%) with influenza, representing 763 unique patients. Fewer than 6 patients had coexisting COVID-19 and influenza (exact value suppressed to limit risk of patient reidentification).

Patient Characteristics

Patients with COVID-19 had a median age of 65 years (IQR 53, 79) which was similar to influenza (median 68 years, IQR 55, 80) and other conditions (median 68 years, IQR 55, 80, SD<0.1) (Table 1). Patients with COVID-19, compared to patients with influenza or other conditions, were more likely to be male (59.1% vs 50.8% and 56.1%, respectively, SD=0.17), more likely to have a Charlson score of zero (54.1% vs. 38.8% and 43.6%, respectively, SD=0.31), more likely to have intermediate or high hospital frailty risk score (37.2% vs 28.2% and 27.3%, respectively, SD=0.22), and more likely to reside in a long-term care facility (11.7% vs 4.5% and 2.9%, respectively, SD=0.34).

Hypertension (34.7%) and diabetes mellitus (27.7%) were common in patients with COVID-19 and occurred at similar rates in influenza and other conditions (Table 1). Neurocognitive disorders (including delirium and dementia) were more common in patients with COVID-19 compared to influenza and other conditions (16.9% vs. 13.4% and 10.1%, respectively, SD=0.20). Chronic obstructive pulmonary disease was more common in patients with influenza (12.3%) than with COVID-19 (5.4%) or other conditions (5.7%, SD=0.25).

Differences in baseline vital signs and laboratory test results are presented in Appendix Table 1. Presenting vital signs did not appear to differ meaningfully across groups, although patients with COVID-19 were more likely to require oxygen within 48 hours of hospitalization (46.0% vs. 40.1% and 21.3.6%, respectively, p <0.001). Patients with COVID-19 were more likely to have arterial blood gases (20.3% vs. 14.3% and 9.6%, p <0.001) and D-dimer measured (38.4% vs. 4.3% and 3.7%, respectively, p<0.001). Patients with COVID-19 had lower arterial pO2 (74.0 vs 81.5 and 108.0, respectively, p<0.001) but no significant difference in D-dimer values (p=0.22).

Mortality and Readmission

Compared to patients with influenza and other conditions, patients with COVID-19 had significantly greater unadjusted in-hospital mortality (19.9% vs 6.1% and 5.9%, respectively, p<0.001, Table 2). Readmission within 7- and 30-days occurred in 4.4% and 8.6% of patients with COVID-19, respectively, which was not significantly different from influenza and other conditions.

Regression model results are reported in Table 3. After adjustment, patients with COVID-19 were more likely to die in hospital compared to patients with influenza (adjusted Relative Risk 3.47, 95% CI: 2.57, 4.67) and other conditions (aRR 3.58, 95% CI: 3.16, 4.06). There was no significant difference in 30-day readmission.

Hospital Resource Use and Clinical Care

Compared to patients with influenza and other conditions, patients with COVID-19 had greater unadjusted ICU use (26.4% vs 18.0% and 23.5%, respectively, p<0.001) and hospital length-of-stay (median 8.7 days vs.4.8 days and 4.4 days, respectively, p<0.001) and shorter ED length-of-stay (median 8.7 hours vs. 21.1 hours and 13.6 hours, respectively p<0.001) (Table 2). COVID-19 patients were more likely to receive invasive mechanical ventilation (18.5% vs 9.3% and 9.7%, respectively) and renal replacement therapy (7.7% vs 5.5% and 4.3%, respectively, p <0.001) but were less likely to receive bronchoscopy or endoscopy (Table 2).

Patients with COVID-19 received at least one thoracic CT in 19.7% of admissions and at least one respiratory-acting antibiotic order in 71.6% of cases, which was similar to influenza and greater than other conditions (Table 2). Patients with COVID-19 received systemic corticosteroids in 16.7% of cases and received either warfarin or a direct-acting oral anticoagulant in 15.4% of cases.

After multivariable adjustment, patients with COVID-19 were more likely to use ICU than patients with influenza (aRR 1.52, 95% CI: 1.27, 1.83) and other conditions (aRR 1.21, 95% CI: 1.09, 1.34). Adjusted total hospital length-of-stay was greater for COVID-19 than influenza (adjusted rate ratio: 1.40, 95%CI: 1.20, 1.64, corresponding to an additional 1.45 days, 95%CI: 0.5, 3.2 days) and other conditions (aRR: 1.79, 95%CI: 1.66, 1.92, corresponding to an additional 4.12 days, 95% CI: 3.03, 5.52 days).

Age-Stratified Outcomes

Age-stratified outcomes are presented in Table 4. Among patients with COVID-19 who were less than 50 years, 50-75 years, and greater than 75 years of age, unadjusted mortality was 5.1%, 13.5%, and 38.9%, respectively; ICU use was 29.8%, 35.2%, and 11.3%, respectively; and 30-day readmission was 11.6%, 8.8%, and 5.7%, respectively.

Intensive Care Unit Admissions

Among patients admitted to the ICU (Table 5), those with COVID-19 were younger than those with influenza or other conditions (median age 59 years vs. 64 years and 66 years, respectively, SD=0.35), more likely to die (25.5% vs 19.9% and 11.9%, respectively, p<0.001) and had longer ICU LOS (median 10.9 days vs 6.0 days and 2.1 days, respectively p<0.001).

Sensitivity Analyses

Results of all analyses were materially unchanged after excluding the 79 COVID-19 admissions without laboratory confirmation of virus infection (data not shown).

To avoid overestimating severity of illness because of interfacility transfers for critical care, we examined the subset of patients admitted from the ED. ED admissions (N=30,533) accounted for 70.3% of all admissions, including 79.8% of COVID-19 admissions, 86.0% of influenza admissions, and 69.7% of other admissions. Admissions for cardiac conditions and procedures were the most common causes of non-ED admissions. Findings were generally similar, except differences in hospital length-of-stay were somewhat attenuated and ICU use was less frequent among COVID-19 patients under 50 years (16.9%) and 50-75 years (24.9%) compared to the overall cohort (29.8% and 35.2%, respectively). Mortality among patients with COVID-19 under 50 years of age was also lower (<3.6% from ED and 5.0% overall). COVID-19 was consistently associated with worse outcomes than influenza and other conditions. See Appendix Tables 2-6 for details.

Discussion

This multicentre cohort study describes patient characteristics, hospital resource use, clinical care, and outcomes for 1,027 adults hospitalized with COVID-19 in Ontario, Canada, during the first wave of the pandemic. To our knowledge, this represents the first detailed characterization of adult hospitalizations for COVID-19 in Canada. These findings can support future efforts to model hospital resource use as the pandemic evolves.36 Even after controlling for age, sex, comorbidity, and residence in long-term care, patients with COVID-19 had 3.5-times greater risk of death in hospital than patients with influenza or other conditions. Patients with COVID-19 were more likely to use ICU and invasive mechanical ventilation and had greater hospital length-of-stay.

Our study contributes to the emerging literature describing hospitalization for COVID-19. Two Canadian case series (involving 117 patients in Vancouver6 and 75 patients in Montreal7) described the care of ICU patients with COVID-19. In these reports, 57-63% of patients required invasive mechanical ventilation and 15-25% of patients died in hospital. Similarly, we found that invasive mechanical ventilation was used in 69% of ICU admissions for COVID-19 and 25% died. ICU care was received in 26% of all COVID-19 admissions, and 18% of those admitted through the ED. We extend this literature by including patients who did not require ICU and by reporting detailed data regarding presenting characteristics, clinical care, resource use, and outcomes. Mortality and ICU use in these Canadian hospitalizations were similar to the United States1–3, China5,37, and the United Kingdom4. We found that 8.7% of patients with COVID-19 were readmitted within 30 days, which is comparable to findings from the United States,3,38 and is important for modeling resource use.

Patients hospitalized with COVID-19 had a median age of 65 years, which was younger than in the United Kingdom (73 years)4 but somewhat older than studies in the United States and China (range 51-63 years)1,2,5,37. Patients with COVID-19 were more likely to be male (59%) and reside in long-term care (12%), which is consistent with evidence that COVID-19 affects men more severely39 and reflects the high burden of COVID-19 in long-term care facilities in Ontario10,11. However, 54% of patients hospitalized with COVID-19 had a Charlson comorbidity score of zero and 21% occurred in people under 50 years of age. Mortality in the younger group was relatively low (5.1% overall and <3.6% among ED admissions) but ICU use (29.8%) and 30-day readmission (11.6%) were high, reinforcing that COVID-19 can cause serious illness in younger people and those with relatively little comorbid disease.

Our study also contributes to comparisons of COVID-19 with seasonal influenza. The infection fatality rate of COVID-19 may be as much as 10-times greater than influenza15,16 but these comparisons are indirect and have been disputed.13 In a systematic review of observational studies, the in-hospital mortality rate of patients with influenza was reported to be approximately 3-6%18, which is similar to our finding (6.1%). After adjusting for age, sex, comorbidity and long-term care residence, compared to influenza, patients with COVID-19 had greater risk of death (3.5-times) and ICU admission (1.5-times), and longer hospital stay (1.4-times). Thus, COVID-19 is substantially more severe than seasonal influenza, and this information could assist with public health messaging.

More than 70% of patients hospitalized with COVID-19 received at least one physician order for respiratory-acting antibiotics, which was comparable to patients hospitalized with influenza. Bacterial co-infection is reported to affect up to 20-30% of ICU patients with influenza40,41 but only 8% of ICU patients with COVID-19.42 Our findings reinforce concerns that antibiotic use in COVID-19 may increase antimicrobial resistance and highlight the importance of future research in this area.

Our study has several limitations. First, we included 7 large academic hospitals. COVID-19 patients were transferred to these hospitals for critical care, which may lead us to overestimate the severity of COVID-19. To address this concern, we compared COVID-19 to influenza and other conditions, for which patients could also have been transferred. We also replicated our analyses in patients admitted through the ED to exclude inter-facility transfers. In this analysis, 20% of COVID-19 patients died in hospital, 18% required ICU, and the mortality rate compared to influenza was even greater (aRR 3.96). We believe our results are generalizable as mortality in our cohort was consistent with large studies from the United States1 and United Kingdom4 and we included approximately 25% of all COVID-19 hospitalizations in Ontario during the study period. Second, although COVID-19 disproportionately affects racial and ethnic minority communities43, data regarding patient race, ethnicity, language, or socioeconomic status is not collected systematically in Ontario hospitals and could not be reported. Third, we were unable to collect information about clinical history or symptoms, as this was not captured systematically in administrative or electronic medical record data. Fourth, we report 30-day readmission to a medical service or medical-surgical ICU at any participating hospital. Although this likely underestimates the total readmission rate, 82% of readmissions occur to the original hospital in our region44, and we were able to also capture readmissions to other participating hospitals. Fifth, the severity of seasonal influenza may vary from year-to-year and we compared COVID-19 only to influenza cases in 2019-2020. However, the mortality associated with influenza hospitalizations in our study (6.1%) is consistent with mortality rates of approximately 3-6% in a systematic review involving more than 120,000 influenza hospitalizations18, suggesting our results are likely generalizable. Finally, vital signs are not consistently recorded electronically at all participating hospitals, particularly when patients are in the emergency department or intensive care unit, which could have led to an underestimation of vital signs abnormalities.

Conclusion

Adults hospitalized with COVID-19 at 7 hospitals in Ontario during the first wave of the pandemic used substantial hospital resources and suffered high rates of mortality. Patients hospitalized with COVID-19 had significantly greater mortality, ICU use, invasive mechanical ventilation use, and hospital length-of-stay than patients with influenza or other conditions.

Data Availability

The data presented in this manuscript are available from the investigators upon reasonable request, and within the constraints placed by local REB approvals and data sharing agreements.

Acknowledgments

We would like to acknowledge Dr. Radha Koppula for performing manual chart abstraction and Mr. Daniel Tamming for contributing to data analysis. We would also like to acknowledge the individuals and organizations that have made the data available for this research.

Footnotes

  • Funding Statement: This project was supported by CIHR Grant VR4-172743. The development of the GEMINI data platform has been supported with funding from the Canadian Cancer Society, the Canadian Frailty Network, the Canadian Institutes of Health Research, the Canadian Medical Protective Association, Green Shield Canada Foundation, the Natural Sciences and Engineering Research Council of Canada, Ontario Health, the St. Michael’s Hospital Association Innovation Fund, the University of Toronto Department of Medicine, and in-kind support from partner hospitals and Vector Institute.

References

  1. 1.↵
    Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA - J Am Med Assoc. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
    OpenUrlCrossRefPubMed
  2. 2.↵
    Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372–2374. doi:10.1056/NEJMc2010419
    OpenUrlCrossRefPubMed
  3. 3.↵
    Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med. 2020;319(5):C945–C945. doi:10.7326/M20-5661
    OpenUrlCrossRef
  4. 4.↵
    Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020;369(March):1–12. doi:10.1136/bmj.m1985
    OpenUrlCrossRef
  5. 5.↵
    Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
    OpenUrlCrossRefPubMed
  6. 6.↵
    Mitra AR, Fergusson NA, Lloyd-Smith E, et al. Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series. Cmaj. 2020;192(26):E694–E701. doi:10.1503/cmaj.200794
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Cavayas YA, Noël A, Brunette V, et al. Early experience with critically ill patients with COVID-19 in Montreal. Can J Anesth. Published online 2020. doi:10.1007/s12630-020-01816-z
    OpenUrlCrossRef
  8. 8.↵
    Johns Hopkins University Coronavirus Resource Centre. MORTALITY ANALYSES. Published 2020. accessed December 5, 2020. https://coronavirus.jhu.edu/data/mortality
  9. 9.↵
    Subedi R, Greenberg L, Turcotte M. StatCan COVID-19_J: Data to Insights for a Better Canada neighbourhoods. 2020;(45280001).
  10. 10.↵
    Liu M, Maxwell CJ, Armstrong P, et al. COVID-19 in long-term care homes in Ontario and British Columbia. Can Med Assoc J. 2020;192(47):cmaj.201860. doi:10.1503/cmaj.201860
    OpenUrlFREE Full Text
  11. 11.↵
    Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk Factors Associated With Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care Facilities in Ontario, Canada. JAMA Netw open. 2020;3(7):e2015957. doi:10.1001/jamanetworkopen.2020.15957
    OpenUrlCrossRef
  12. 12.↵
    Tolksdorf K, Buda S, Schuler E, Wieler LH, Haas W. Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19). Eurosurveillance. 2020;25(11). doi:10.2807/1560-7917.ES.2020.25.11.2000258
    OpenUrlCrossRefPubMed
  13. 13.↵
    Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020;188(January):109890. doi:10.1016/j.envres.2020.109890
    OpenUrlCrossRefPubMed
  14. 14.
    World Health Organization. Coronavirus disease (COVID-19): Similarities and differences with influenza. accessed December 10, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19-similarities-and-differences-with-influenza
  15. 15.↵
    Brazeau NF, Verity R, Jenks S, et al. Report 34 - COVID-19 Infection Fatality Ratio Estimates from Seroprevalence. 2020;(October):1–18. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-34-ifr/
  16. 16.↵
    Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. Bmj. Published online 2020:m4509. doi:10.1136/bmj.m4509
    OpenUrlAbstract/FREE Full Text
  17. 17.
    Tolksdorf K, Buda S, Schuler E, Wieler LH, Haas W. Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19). Eurosurveillance. 2020;25(11). doi:10.2807/1560-7917.ES.2020.25.11.2000258
    OpenUrlCrossRefPubMed
  18. 18.↵
    Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2020;(September). doi:10.1002/rmv.2179
    OpenUrlCrossRef
  19. 19.↵
    Verma AA, Guo Y, Kwan JL, et al. Patient characteristics, resource use and outcomes associated with general internal medicine hospital care: the General Medicine Inpatient Initiative (GEMINI) retrospective cohort study. C Open. 2017;5(4):E842–E849. doi:10.9778/cmajo.20170097
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    Verma AA, Pasricha S V, Jung HY, et al. Assessing the quality of clinical and administrative data extracted from hospitals: the General Medicine Inpatient Initiative (GEMINI) experience. J Am Med Informatics Assoc. Published online November 4, 2020:2020.03.16.20036962. doi:10.1093/jamia/ocaa225
    OpenUrlCrossRef
  21. 21.↵
    Canadian Institute for Health Information. ICD-10-CA Coding Direction for Suspected COVID-19 Cases. Published 2020. accessed November 19, 2020. https://www.cihi.ca/en/bulletin/icd-10-ca-coding-direction-for-suspected-covid-19-cases
  22. 22.↵
    Mulpuru S, Smith T, Lawrence N, Wilson K, Forster AJ. Evaluation of 3 electronic methods used to detect influenza diagnoses during 2009 pandemic. Emerg Infect Dis. 2013;19(12):2062–2063. doi:10.3201/eid1912.131012
    OpenUrlCrossRef
  23. 23.↵
    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(SUPPL. 2). doi:10.1086/511159
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.
    Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST
    OpenUrlCrossRefPubMed
  25. 25.↵
    Dragan V, Wei Y, Elligsen M, Kiss A, Walker SAN, Leis JA. Prophylactic Antimicrobial Therapy for Acute Aspiration Pneumonitis. Clin Infect Dis. 2018;67(4):513–518. doi:10.1093/cid/ciy120
    OpenUrlCrossRef
  26. 26.↵
    Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med. Published online 2020:1-11. doi:10.1056/nejmoa2021436
    OpenUrlCrossRefPubMed
  27. 27.↵
    Godoy LC, Goligher EC, Lawler PR, Slutsky AS, Zarychanski R. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. Cmaj. 2020;192(40):E1156–E1161. doi:10.1503/cmaj.201240
    OpenUrlFREE Full Text
  28. 28.↵
    Healthcare Cost and Utilization Project. Clinical classifications software refined (CCSR) for ICD-10-CM diagnoses. Published 2020. accessed December 10, 2020. https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp
  29. 29.↵
    Verma AA, Guo Y, Kwan JL, et al. Prevalence and Costs of Discharge Diagnoses in Inpatient General Internal Medicine: a Multi-center Cross-sectional Study. J Gen Intern Med. 2018;33(11):1899–1904. doi:10.1007/s11606-018-4591-7
    OpenUrlCrossRef
  30. 30.↵
    Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq433
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet (London, England). 2018;391(10132):1775–1782. doi:10.1016/S0140-6736(18)30668-8
    OpenUrlCrossRefPubMed
  32. 32.↵
    McAlister F, van Walraven C. External validation of the Hospital Frailty Risk Score and comparison with the Hospital-patient One-year Mortality Risk Score to predict outcomes in elderly hospitalised patients: a retrospective cohort study. BMJ Qual Saf. 2019;28(4):284–288. doi:10.1136/bmjqs-2018-008661
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Commun Stat - Simul Comput. 2009;38(6):1228–1234. doi:10.1080/03610910902859574
    OpenUrlCrossRefWeb of Science
  34. 34.↵
    Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–706. doi:10.1093/aje/kwh090
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    Ontario) OA for HP and P (Public H. Epidemiologic Summary: COVID-19 in Ontario - January 15, 2020 to June 30, 2020.; 2020. https://files.ontario.ca/moh-covid-19-report-en-2020-07-01.pdf
  36. 36.↵
    Barrett K, Khan YA, MBiotech S Mac, Ximenes R, Naimark DMJ, Sander B. Estimation of covid-19induced depletion of hospital resources in ontario, Canada. Cmaj. 2020;192(24):E640–E646. doi:10.1503/cmaj.200715
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi:10.1001/jamainternmed.2020.0994
    OpenUrlCrossRefPubMed
  38. 38.↵
    Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing. Morb Mortal Wkly Rep. 2020;69(Early Release):1695–1699.
    OpenUrl
  39. 39.↵
    Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;(June). doi:10.1038/s41586-020-2700-3
    OpenUrlCrossRefPubMed
  40. 40.↵
    Shah NS, Greenberg JA, McNulty MC, et al. Bacterial and viral co-infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013–14. J Clin Virol. 2016;80:12–19. doi:10.1016/j.jcv.2016.04.008
    OpenUrlCrossRef
  41. 41.↵
    Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States*. Crit Care Med. 2012;40(5):1487–1498. doi:10.1097/CCM.0b013e3182416f23
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;(xxxx). doi:10.1016/j.cmi.2020.07.016
    OpenUrlCrossRefPubMed
  43. 43.↵
    Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States. Clin Infect Dis. Published online June 20, 2020. doi:10.1093/cid/ciaa815
    OpenUrlCrossRef
  44. 44.↵
    Staples JA, Thiruchelvam D, Redelmeier DA. Site of hospital readmission and mortality: a population-based retrospective cohort study. C Open. 2014;2(2):E77–E85. doi:10.9778/cmajo.20130053
    OpenUrlAbstract/FREE Full Text
Back to top
Posted December 16, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Patient characteristics, clinical care, resource use, and outcomes associated with hospitalization for COVID-19 in the Toronto area
Amol A. Verma, Tejasvi Hora, Hae Young Jung, Michael Fralick, Sarah L. Malecki, Lauren Lapointe-Shaw, Adina Weinerman, Terence Tang, Janice L. Kwan, Jessica J. Liu, Shail Rawal, Timothy C.Y. Chan, Angela M. Cheung, Laura C. Rosella, Marzyeh Ghassemi, Margaret Herridge, Muhammad Mamdani, Fahad Razak
medRxiv 2020.12.15.20248199; doi: https://doi.org/10.1101/2020.12.15.20248199
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area